Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints
Marcel M Levi, Manon E. Cromheecke, Evert de Jonge et al. · The Lancet · 1999
Cited by 545 works. doi:10.1016/s0140-6736(99)01264-7
Authors
- Marcel M Levi
- Manon E. Cromheecke
- Evert de Jonge
- Martin H. Prins
- Bas A.J.M. de Mol
- Ernest Briët
- Harry Roger Buller
References
- EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY
- Treatment with Desmopressin Acetate to Reduce Blood Loss after Cardiac Surgery
- Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)
- Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
- Bleeding after Cardiopulmonary Bypass
- Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery
- Prophylactic tranexamic acid decreases bleeding after cardiac operations
- Hemostatic Drugs
- A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting
- Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass